Pathway Therapeutics Limited Completes $4.5 Million Financing for Novel PI3K Inhibitor Portfolio

Published: Aug 10, 2010

SAN FRANCISCO--(BUSINESS WIRE)--Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

Back to news